Figure 2From: Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancerSurvival in patents with platinum refractory or resistant epithelial ovarian cancer.Back to article page